Autophagy in blood cancers: biological role and therapeutic implications

Autophagy is a cell recycling process the molecular apparatus of which has been identified over the past decade. Autophagy allows cells to survive starvation and inhospitable conditions and plays a key role in numerous physiological functions, including hematopoiesis and immune responses. In hematologic malignancies, autophagy can either act as a chemo-resistance mechanism or have tumor suppressive functions, depending on the context. In addition, autophagy is involved in other important aspects of blood cancers as it promotes immune competence and anti-cancer immunity, and may even help enhance patient tolerance to standard treatments. Approaches exploiting autophagy, either to activate or inhibit it, could find broad application in hematologic malignancies and contribute to improved clinical outcomes. These aspects are discussed here together with a brief introduction to the molecular machinery of autophagy and to its role in blood cell physiology.

[1]  T. Morgan,et al.  Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression , 2013, Experimental Gerontology.

[2]  D. Colomer,et al.  Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma , 2013, Autophagy.

[3]  D. White,et al.  Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy , 2013, Leukemia & lymphoma.

[4]  R. Stahel,et al.  Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin , 2012, BMC Cancer.

[5]  G. Bhagat,et al.  Akt-Mediated Regulation of Autophagy and Tumorigenesis Through Beclin 1 Phosphorylation , 2012, Science.

[6]  S. Altiok,et al.  Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. , 2012, Cancer research.

[7]  J. McCubrey,et al.  Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia , 2012, Leukemia.

[8]  M. Bogyo,et al.  Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. , 2012, Blood.

[9]  N. Munshi,et al.  Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. , 2012, Blood.

[10]  B. Zhivotovsky,et al.  Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. , 2012, Cancer research.

[11]  P. Conti,et al.  Fasting Enhances the Response of Glioma to Chemo- and Radiotherapy , 2012, PloS one.

[12]  K. Schlie,et al.  Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity , 2012, Immunological reviews.

[13]  D. Ribatti,et al.  Antiangiogenic therapeutic approaches in multiple myeloma. , 2012, Current cancer drug targets.

[14]  David B. Allison,et al.  Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study , 2012, Nature.

[15]  M. Priault,et al.  Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence , 2012, Cell Death and Disease.

[16]  A. Thorburn,et al.  The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. , 2012, Cancer research.

[17]  V. Deretic Autophagy: An Emerging Immunological Paradigm , 2012, The Journal of Immunology.

[18]  A. Ballestrero,et al.  Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. , 2012, Seminars in hematology.

[19]  S. Grant,et al.  Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. , 2012, Blood.

[20]  J. Tamburini,et al.  The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia , 2012, Leukemia.

[21]  R. Xiang,et al.  Abstract 3535: Lymphoma-associated macrophages benefit for tumor progress via overexpressing legumain to degrade extracellular matrix in diffuse large B-cell lymphoma , 2012 .

[22]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[23]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[24]  W. Qian,et al.  Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro , 2012, Acta Pharmacologica Sinica.

[25]  Vito Pistoia,et al.  Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy , 2012, Science Translational Medicine.

[26]  M. Prætorius-Ibba,et al.  FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma , 2012, Autophagy.

[27]  A. Carella,et al.  Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia , 2012, Leukemia & lymphoma.

[28]  Kai-Chien Yang,et al.  Lapatinib Induces Autophagy, Apoptosis and Megakaryocytic Differentiation in Chronic Myelogenous Leukemia K562 Cells , 2011, PloS one.

[29]  J. Byrd,et al.  FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. , 2011, Blood.

[30]  E. Unanue,et al.  Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells , 2011, The Journal of experimental medicine.

[31]  M. Eisenstein,et al.  The autophagy protein Atg12 associates with antiapoptotic Bcl-2 family members to promote mitochondrial apoptosis. , 2011, Molecular cell.

[32]  Jie Sun,et al.  Autophagy Inhibition Enhances Daunorubicin-Induced Apoptosis in K562 Cells , 2011, PloS one.

[33]  J. Ruan Antiangiogenic therapies in non-Hodgkin's lymphoma. , 2011, Current cancer drug targets.

[34]  W. Fiedler,et al.  Clinical experience with antiangiogenic therapy in leukemia. , 2011, Current cancer drug targets.

[35]  M. Priault,et al.  ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells , 2011, Autophagy.

[36]  D. Rubinsztein,et al.  Autophagy and Aging , 2011, Cell.

[37]  D. Rubinsztein,et al.  Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. , 2011, The Journal of clinical investigation.

[38]  H. Ke,et al.  Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13 , 2011, Cell.

[39]  T. Holyoake,et al.  Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. , 2011, Blood.

[40]  E. Morselli,et al.  p53 inhibits autophagy by interacting with the human ortholog of yeast Atg17, RB1CC1/FIP200 , 2011, Cell cycle.

[41]  Andrea Ballabio,et al.  TFEB Links Autophagy to Lysosomal Biogenesis , 2011, Science.

[42]  H. Nakano,et al.  An unexpected role for autophagy in degranulation of mast cells , 2011, Autophagy.

[43]  J. McCubrey,et al.  Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia , 2011, Leukemia.

[44]  Seamus J. Martin,et al.  Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. , 2011, Molecular cell.

[45]  B. Yan,et al.  Discovery of small molecules that target autophagy for cancer treatment. , 2011, Current medicinal chemistry.

[46]  E. Soilleux,et al.  The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance , 2011, The Journal of experimental medicine.

[47]  B. Viollet,et al.  AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.

[48]  B. Viollet,et al.  Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.

[49]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[50]  S. Morrison,et al.  FIP200 is required for the cell-autonomous maintenance of fetal hematopoietic stem cells. , 2010, Blood.

[51]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[52]  O. Ilkayeva,et al.  Autophagy is Essential to Suppress Cell Stress and to Allow BCR-Abl-Mediated Leukemogenesis , 2010, Oncogene.

[53]  A. Ballestrero,et al.  Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. , 2010, Experimental hematology.

[54]  G. Kroemer,et al.  Autophagy and the integrated stress response. , 2010, Molecular cell.

[55]  H. Mitsuya,et al.  Clarithromycin attenuates autophagy in myeloma cells. , 2010, International journal of oncology.

[56]  M. Bjørås,et al.  Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. , 2010, Blood.

[57]  K. Anderson,et al.  PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. , 2010, Blood.

[58]  J. Debnath,et al.  ATG12 Conjugation to ATG3 Regulates Mitochondrial Homeostasis and Cell Death , 2010, Cell.

[59]  W. Kiosses,et al.  Short-term fasting induces profound neuronal autophagy , 2010, Autophagy.

[60]  H. Nagawa,et al.  The inhibition of autophagy potentiates anti-angiogenic effects of sulforaphane by inducing apoptosis , 2010, Angiogenesis.

[61]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[62]  S. Minucci,et al.  Histone deacetylases and epigenetic therapies of hematological malignancies. , 2010, Pharmacological research.

[63]  Paul Workman,et al.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic. , 2010, Cancer research.

[64]  P. Cohen,et al.  Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. , 2010, Cancer research.

[65]  G. Robert,et al.  Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. , 2010, Cancer research.

[66]  V. Longo,et al.  Calorie restriction and cancer prevention: metabolic and molecular mechanisms. , 2010, Trends in pharmacological sciences.

[67]  D. Ferguson,et al.  Loss of autophagy in erythroid cells leads to defective removal of mitochondria and severe anemia in vivo , 2009, Proceedings of the National Academy of Sciences.

[68]  T. Dorff,et al.  Fasting and cancer treatment in humans: A case series report , 2009, Aging.

[69]  M. Dyer,et al.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. , 2009, The Journal of clinical investigation.

[70]  P. Greaney,et al.  The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. , 2009, Blood.

[71]  J. Jankovic,et al.  Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement , 2008, Neurobiology of Disease.

[72]  Ying Zhao,et al.  Vitamin D3 Induces Autophagy of Human Myeloid Leukemia Cells* , 2008, Journal of Biological Chemistry.

[73]  C. Thompson,et al.  Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. , 2008, Blood.

[74]  Changhan Lee,et al.  Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy , 2008, Proceedings of the National Academy of Sciences.

[75]  J. Guan,et al.  FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells , 2008, The Journal of cell biology.

[76]  Nektarios Tavernarakis,et al.  Regulation of autophagy by cytoplasmic p53 , 2008, Nature Cell Biology.

[77]  K. Nakayama,et al.  Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. , 2008, Blood.

[78]  S. Kondo,et al.  Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. , 2008, Experimental hematology.

[79]  Nicholas E. Bruns,et al.  A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy , 2008, Proceedings of the National Academy of Sciences.

[80]  John L Cleveland,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes , 2008, Autophagy.

[81]  S. Ramakrishnan,et al.  Autophagy and Angiogenesis Inhibition , 2007, Autophagy.

[82]  J. Cleveland,et al.  Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.

[83]  J. Duyster,et al.  The anticancer drug imatinib induces cellular autophagy , 2007, Leukemia.

[84]  Jie Jin,et al.  Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. , 2007, Leukemia research.

[85]  M. Berger,et al.  DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells , 2007, Cell Death and Differentiation.

[86]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.

[87]  You-Wen He,et al.  A critical role for the autophagy gene Atg5 in T cell survival and proliferation , 2007, The Journal of experimental medicine.

[88]  P. Finn,et al.  Proteolytic and lipolytic responses to starvation. , 2006, Nutrition.

[89]  Y. Kondo,et al.  Autophagy and Cancer Therapy , 2006, Autophagy.

[90]  G. D. De Meyer,et al.  In Situ Detection of Starvation-induced Autophagy , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[91]  Govind Bhagat,et al.  Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. , 2003, The Journal of clinical investigation.

[92]  Arnold J. Levine,et al.  Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[93]  H. Hibshoosh,et al.  Induction of autophagy and inhibition of tumorigenesis by beclin 1 , 1999, Nature.

[94]  Takeshi Noda,et al.  Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in Yeast* , 1998, The Journal of Biological Chemistry.

[95]  P. Allen,et al.  Inhibition of autophagy abrogates tumour necrosis factor α induced apoptosis in human T‐lymphoblastic leukaemic cells , 1997, British journal of haematology.

[96]  M. Rechsteiner,et al.  Degradation of microinjected proteins: Effects of lysosomotropic agents and inhibitors of autophagy , 1983, Journal of cellular physiology.

[97]  K. Saeki [Degranulation of mast cells]. , 1983, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[98]  D. Azarnoff Drug interactions: Clinical significance , 1974, Clinical pharmacology and therapeutics.

[99]  J. McCubrey,et al.  AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications , 2012, Leukemia.

[100]  R. Arceci,et al.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival , 2012 .

[101]  D. Rubinsztein,et al.  Chemical modulators of autophagy as biological probes and potential therapeutics. , 2011, Nature chemical biology.

[102]  J. Johnston,et al.  p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. , 2011, Leukemia research.

[103]  A. Ballestrero,et al.  Proteasome inhibitors: antitumor effects and beyond , 2007, Leukemia.